This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The following outcomes were assessed: patient survival based on stage at diagnosis, the cancer detection rate in the three groups, the interval cancer rate, and deaths (from breast cancer and other causes at different ages).
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Approximately 6 studies were included in the review.
Methods of combining primary studies
The primary studies were not combined.
Investigation of differences between primary studies
Differences between the primary studies were not reported and it was unclear if any were investigated.
Results of the review
The cancer detection rate was 3.2 per 1,000 women without CAD and 3.8 per 1,000 women with CAD.
The probability of a palpable mass was 0.01576. The positive predictive value of biopsy was 0.38.
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Measure of benefits used in the economic analysis
The measure of benefit used in an incremental cost-effectiveness analysis was the additional life-years gained.
Direct costs
The costs were examined from the perspective of the third-party payer. The costs of procedures and imaging were based on average Medicare reimbursement in 2003. The cost of treatment was based on data from studies in the literature. The marginal cost was calculated as the difference between comparison groups. Discounting was carried out, which was appropriate as the costs were incurred during more than 2 years. Although the resource quantities were not reported separately, the unit costs were reported. The estimation of quantities was derived using modelling. The results were expressed in 2003 US dollars.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The authors reported that a societal perspective was adopted for this analysis and all costs were counted, regardless of who incurred them. However, the indirect costs (productivity losses) included were not specified.
Currency

US dollars ($).
Sensitivity analysis
One-way sensitivity analyses were performed in order to examine cost-effectiveness after altering various parameters used for the reference case calculations. The breast cancer detection rates for mammography with and without CAD and the interval cancer rate were varied in the sensitivity analysis. The ranges selected for the sensitivity analysis were based on authors' assumptions. A sensitivity analysis with different stage distribution of breast cancers, as diagnosed by the various methods, was also conducted on the basis of distributions suggested by an expert. The costs were also subjected to sensitivity analysis. The cost of CAD was varied on the basis of authors' assumptions, while the costs of treating cancer at different stages were varied based on the literature.
Estimated benefits used in the economic analysis
The marginal effectiveness of mammography alone versus observation was 0.0823 life-years, while that of mammography with CAD versus mammography alone was 0.0285 life-years.
Cost results
The total cost for each strategy was not reported.
The marginal cost of mammography versus observation was $1,318.43, while that of mammography with CAD versus mammography alone was $448.45.
Synthesis of costs and benefits
The marginal cost per life-year saved (MCYLS) for screening mammography alone was $16,023. The addition of CAD to the mammography programme resulted in an MCYLS of $19,058.
Adding CAD to a mammography screening programme increased the marginal effectiveness of screening by 29% and the marginal cost of the programme by 34%.
